Burbridge, Claire
Randall, Jason A.
Sanchez, Robert J.
Dansky, Hayes
Symonds, Tara
Girman, Cynthia J.
Strayer, Joshua A.
Selk, Karen L.
Whitcomb, David C.
Kershaw, Erin E.
Funding for this research was provided by:
Regeneron Pharmaceuticals (RG1012C)
Article History
First Online: 27 June 2019
Compliance with Ethical Standards
:
: This study was funded by Regeneron Pharmaceuticals, Inc. (No. RG1012C).
: CJG has received fees/honorarium as a consultant to Regeneron; DCW has received fees/honorarium for providing expert opinion on pancreatic disease; JAR, TS, and CB are employees of Clinical Outcomes Solutions, which received funding from Regeneron; HD and RJS are employees of Regeneron and received salary and stocks/stock options; KLS received compensation for patient recruitment for Regeneron; and JAS and EEK have declared no conflict of interest.
: This study was reviewed and approved by the University of Pittsburgh Institutional Review Board (IRB) (3500 Fifth Ave., Pittsburgh, PA 15213, USA;ExternalRef removed). The IRB approved a waiver for the requirement to obtain informed consent to use protected health information to identify potential research subjects for recruitment purposes only, however all participants were then asked to provide informated consent prior to engaging in the study (IRB #: PRO16110537).The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.